PRP vs. Corticosteroid Injections for Knee Osteoarthritis: Which Offers Longer Pain Relief?
Published November 16, 2026
Protocol: 6 steps in this guide
Some trials suggest that relief from platelet-rich plasma (PRP) may last longer than relief from a corticosteroid injection, while others, including a four-arm trial in which PRP, corticosteroid and hyaluronic acid showed no superiority over placebo in the patients studied, found no PRP advantage; the evidence is mixed and does not guarantee a longer result for any individual. A 2025 systematic review of six randomized trials states: “Some studies indicate that PRP injections may offer prolonged benefits, although there is no consensus on whether one treatment is superior.” A 2024 European consensus graded the longer-effect statement A. The 2026 VA/DoD guideline, by contrast, suggests a corticosteroid injection for persistent knee osteoarthritis pain and finds insufficient evidence to recommend for or against PRP.
Knee osteoarthritis and the two injections
Both injections go into the knee joint, but they are different treatments. A corticosteroid is an anti-inflammatory medicine. PRP is made from the patient’s own blood, concentrating platelets into plasma; how it is made is covered in how platelet-rich plasma is made from a blood sample. The VA/DoD guideline describes PRP’s proposed action as releasing “growth factors and signaling molecules that are believed to help modulate inflammation, support tissue healing, and potentially facilitate repair processes,” while noting that its own focus was on patient-centered outcomes.
How the two compare over time
The 2025 review in Cureus, Efficacy and Safety of Intra-articular Platelet-Rich Plasma Versus Corticosteroid Injections, included six randomized trials published from 2019 to 2024. The table below takes each result from the trial publication itself, because two different questions are easy to mix up: whether patients improved over time within each group, and whether PRP did better than the steroid. Only the second answers which injection is better.
| Trial | Who was compared | Scales and follow-up | PRP versus steroid, as the trial reports it |
|---|---|---|---|
| Elksniņš-Finogejevs and colleagues, 2020 | 40 patients randomized; 36 analyzed (19 PRP, 17 steroid) | VAS pain, IKDC and KSS function; 1 week to 1 year | No difference up to 5 weeks; PRP better on all three scales from 15 weeks to 1 year (VAS at 1 year 2.9 vs 5.1, p = 0.0008) |
| Pretorius and colleagues, 2022 | 29 patients, 58 knees; each patient had PRP in one knee and steroid in the other | WOMAC total and pain rating; 6 weeks to 6 months | Both knees improved; no significant difference between the treatments (WOMAC p = 0.84; pain p = 0.85) |
| Nunes-Tamashiro and colleagues, 2022 | 100 patients in three arms: PRP, triamcinolone hexacetonide, saline | VAS, WOMAC and other measures; 4 to 52 weeks | Steroid better than PRP for WOMAC total and pain at 4 weeks; both better than saline for WOMAC function; no PRP advantage over steroid reported in the abstract |
| de Menezes Freire and colleagues, 2020 | 50 patients, 25 per group | WOMAC total and KSS; 1 and 6 months | Both groups improved; PRP better on WOMAC and KSS at 6 months |
| Huang and colleagues, 2019 | 120 patients in three arms of 40: PRP, hyaluronic acid, steroid | WOMAC at 3 to 12 months; VAS before treatment and at 12 months | No difference at 3 months; PRP better on WOMAC at 6, 9 and 12 months |
| Tschopp and colleagues, 2023 | 120 knees in 95 patients; four arms of 30 knees: steroid, hyaluronic acid, PRP, placebo | NRS pain over the first 6 months (primary), WOMAC; questionnaires to 24 months | PRP, steroid and hyaluronic acid showed no superiority over placebo, in patients with low baseline pain and early- to middle-stage OA (time-by-treatment p = 0.25 for the primary outcome) |
Read across the rows, three trials report PRP ahead of the steroid at later follow-up, and three found no PRP advantage. In one of those three (Nunes-Tamashiro), the steroid did better at 4 weeks, and in the four-arm Tschopp trial, PRP, corticosteroid and hyaluronic acid showed no superiority over placebo on the primary pain outcome, in a group with low baseline pain and early- to middle-stage osteoarthritis. Improvement over time within both groups does not establish that PRP is superior to corticosteroid, and the trials used different scales, time points and units: Pretorius counted knees, with each patient as their own control, and Tschopp randomized knees rather than people. The four trials with full text available are Elksniņš-Finogejevs, Pretorius, de Menezes Freire and Tschopp; the other two are Nunes-Tamashiro and colleagues in Clinical Rehabilitation and Huang and colleagues in Der Orthopäde.
In one trial, the review reports, the greatest pain improvement came at three months with PRP and at one month with the steroid. The review also describes PRP pain improvement sustained to about seven months while the steroid group worsened after 15 weeks. The pattern, in the review’s words: “While CS injections provide immediate symptomatic relief, PRP has demonstrated sustained benefits in pain reduction and long-term functional improvement.” But the three trials without a PRP advantage include both trials that also had a saline or placebo arm, and the abstract stresses that there is “no consensus on whether one treatment is superior.” The trials used different PRP preparations and follow-up periods.
Pain measures and meaningful change
The review reports pain on a visual analog scale (VAS) and function with WOMAC, a knee osteoarthritis questionnaire. A statistically significant difference is not automatically one a patient would notice; the VA/DoD guideline notes that some reported PRP improvements “approached or met minimum clinically important difference (MCID) thresholds.” What those thresholds mean is covered in what clinically meaningful improvement means in a joint pain study.
Side effects and repeat injections
The 2025 review reported that “no serious adverse events” occurred in the included studies, with minor, transient side effects such as pain, nausea or local discomfort. One trial reported steroid-group events including facial flushing, palpitations and knee swelling in one patient and nausea and vomiting in another. The VA/DoD guideline notes that adverse effects “were reported more frequently with PRP compared with placebo,” generally mild and self-limited. Repeat steroid injections are a separate question with their own risks; PRP risks are covered in the main risks of a PRP injection.
Why the guidelines disagree
The 2024 European ESSKA-ORBIT consensus (Laver and colleagues, Knee Surgery, Sports Traumatology, Arthroscopy) gave a grade A recommendation, with very strong agreement, to the statement that “PRP injections have been shown to provide a longer effect in comparison to the short-term effect of CS injections.” The 2026 VA/DoD Clinical Practice Guideline for the Non-Surgical Management of Hip & Knee Osteoarthritis reaches different conclusions:
- For persistent knee osteoarthritis pain inadequately relieved by other treatments, it suggests “an intra-articular corticosteroid injection” (weak for).
- It finds “insufficient evidence to recommend for or against platelet-rich plasma” for knee osteoarthritis.
The VA/DoD panel explains its caution about PRP: trial populations “were generally younger, had lower BMI, and had earlier-stage KOA” than many of its patients, blinding “was likely incomplete in many trials,” and “studies at higher risk of bias tended to report larger treatment effects.” The two documents differ in method, date and audience; neither is a direct trial. The broader PRP picture is in what the evidence says about PRP for knee osteoarthritis.
Choosing based on your situation
A reasonable conversation with a clinician covers how advanced the arthritis is, how quickly relief is needed, how long previous steroid injections helped, cost, and what else is planned, such as exercise. On cost, the American Academy of Orthopaedic Surgeons’ patient page on platelet-rich plasma notes that few insurance plans “provide even partial reimbursement,” as discussed in what PRP treatment costs and what drives the price. Neither injection rebuilds cartilage. The comparison with hyaluronic acid is covered in how PRP and hyaluronic acid compare for knee osteoarthritis function.
Three of six randomized trials found PRP ahead of a steroid at later follow-up and three found no PRP advantage, the trials are small and guidelines disagree, so PRP cannot be promised to give longer relief to any individual with knee osteoarthritis.
Cells linked to this one
This guide leads on to
- B1 How Is Platelet-Rich Plasma Made From a Blood Sample?
- I9 What Does Clinically Meaningful Improvement Mean in a Joint Pain Study?
- B10 What Are the Main Risks of a PRP Injection?
- C1 What Does the Evidence Say About PRP for Knee Osteoarthritis?
- B11 What Does PRP Treatment Cost, and What Drives the Price?
- H2 PRP vs. Hyaluronic Acid for Knee Osteoarthritis: How Do Functional Outcomes Compare?
Add a remark